Hemophilia

Novo Nordisk looks to bluebird for gene therapy targets

10-Oct-2019 By Ben Hargreaves

Novo Nordisk partners with bluebird on a three-year research arrangement looking to discover gene therapy candidates for the treatment of genetic diseases, including hemophilia.

Spotlight

Biocon biosimilar business valued at $3bn in funding round

Yposkesi doubles manufacturing footprint to meet AAVs growing demand

Industry equipment is causing a ‘data deficit’, says Fujifilm exec

Astellas acquires Xyphos and its CAR-T technology for $665m

China approves first vaccine since adoption of tougher standards

Products

Eppendorf for Bioprocess – Solutions that grow with you | Download Application Note Perfusion Using an ATF Cell Retention Device
Eppendorf for Bioprocess – Solutions that grow with you | Download Application Note Microaerobic Fermentation of Lactobacillus acidophilus
Eppendorf for Bioprocess – Solutions that grow with you | Download Application Note rAAV Production in BioBLU® Single-Use Vessels
Roquette Pharma Solutions | Download Case Study Learn more about KLEPTOSE® BioPharma for your protein stability challenges
Eppendorf for Bioprocess – Solutions that grow with you | Download Application Note Small-Scale Cell Culture Perfusion Process
MilliporeSigma | Watch Business Advice The Power of Collaboration: M Lab™ Collaboration Centers

Webinars

On-demand webinars

Marken Exploring the value of home visits in clinical trials, the benefits gained by both the patient and the sponsor

Featured Suppliers

All suppliers

Baxter BioPharma Solutions

Bio-Rad Laboratories

Marken

Hemophilia

Novo Nordisk looks to bluebird for gene therapy targets

Spotlight

Follow us

Products

Webinars

Featured Suppliers

Free newsletter sign up

BioPharma-Reporter

Resources